ArticleAsian Pacific journal of cancer prevention : APJCP2025
Anti- Cancer Potential of Diosgenin, a Steroidal Saponin, against Human Oral Cancer Cells.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOral squamous cell carcinoma (OSCC), affecting the lip and oral cavity, is one of the most prevalent cancers worldwide with the highest morbidity rate in the North-Eastern region of India. The current treatment options including surgery and chemotherapy are plagued by adverse side-effects and emergence of chemo-resistance, particularly against drugs like cisplatin and 5-fluorouracil. The present study focuses on demonstrating the effects of diosgenin, a naturally occurring steroidal saponin, on the survival, proliferation, and migration of OSCC cells in vitro.
methodsPreliminary in vitro screening of diosgenin in OSCC cells was performed using MTT, colony formation, cell cycle arrest, PI-FACS, live/dead, and wound-healing assays. In addition, the potential of diosgenin in regulating the expression of critical proteins involved in OSCC was evaluated using western blot analysis.
resultThe present study shows that diosgenin exhibited selective anti-proliferative activity on OSCC cell lines SAS and HSC3 compared to normal kidney cell line HEK-293T. In addition, it enhances the chemosensitivity of SAS cells to cisplatin and 5-FU. This compound also displayed anti-clonogenic, cell cycle arrest, cytotoxic, and anti-migratory effects on SAS cells in a dose-dependent manner. Further, diosgenin regulated the expressions of COX-2, CXCR-4, VEGF, TWIST-1, p-AKT, and AKT, which are critical proteins for the development and progression of OSCC.
conclusionThese findings support the therapeutic potential of diosgenin, thereby opening a new avenue for oral cancer therapy. Nonetheless, the data needs to be further validated in in vivo and clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.